Gene therapy for vein graft disease
Division of Cardiovascular Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Current Cardiology Reports
(Impact Factor: 1.93).
02/2001; 3(1):22-8. DOI: 10.1007/s11886-001-0006-0
The durability of coronary artery bypass grafting is intrinsically dependent upon the patency of the graft. The long term patency of arterial grafts, in particular internal mammary grafts, has been clearly defined by multiple groups to be greater than 90% at 10-20 years following construction. This has been fully addressed in Chaps. 13 and 14. Moreover, a recent randomized trial between radial artery and saphenous vein grafts demonstrated the superiority of radial artery conduits at 1 year .However, certain clinical scenarios require the use of venous grafts. The intrinsic limitations of saphenous vein bypass grafts and the subsequent acceptance of these imperfections guide our clinical decisions in a fundamental fashion. To address these shortcomings in saphenous vein grafts, a growing body of research has endeavored to improve the function of saphenous veins in an attempt to ultimately increase patency rates and durability of the surgical revascularization.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.